252 related articles for article (PubMed ID: 35483477)
1. Pharmacological effects of cannabidiol by transient receptor potential channels.
Etemad L; Karimi G; Alavi MS; Roohbakhsh A
Life Sci; 2022 Jul; 300():120582. PubMed ID: 35483477
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
3. Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals.
Galaj E; Xi ZX
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374481
[TBL] [Abstract][Full Text] [Related]
4. Pure Δ
Romano B; Pagano E; Orlando P; Capasso R; Cascio MG; Pertwee R; Marzo VD; Izzo AA; Borrelli F
Pharmacol Res; 2016 Nov; 113(Pt A):199-208. PubMed ID: 27498155
[TBL] [Abstract][Full Text] [Related]
5. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
6. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB
Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874
[TBL] [Abstract][Full Text] [Related]
7. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
8. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
[TBL] [Abstract][Full Text] [Related]
10. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.
Fride E; Ponde D; Breuer A; Hanus L
Neuropharmacology; 2005 Jun; 48(8):1117-29. PubMed ID: 15910887
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol activation of vagal afferent neurons requires TRPA1.
Kowalski CW; Ragozzino FJ; Lindberg JEM; Peterson B; Lugo JM; McLaughlin RJ; Peters JH
J Neurophysiol; 2020 Nov; 124(5):1388-1398. PubMed ID: 32965166
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid Ligands Targeting TRP Channels.
Muller C; Morales P; Reggio PH
Front Mol Neurosci; 2018; 11():487. PubMed ID: 30697147
[TBL] [Abstract][Full Text] [Related]
13. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
[TBL] [Abstract][Full Text] [Related]
14. Diversity of molecular targets and signaling pathways for CBD.
de Almeida DL; Devi LA
Pharmacol Res Perspect; 2020 Dec; 8(6):e00682. PubMed ID: 33169541
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT
Galaj E; Bi GH; Yang HJ; Xi ZX
Neuropharmacology; 2020 May; 167():107740. PubMed ID: 31437433
[TBL] [Abstract][Full Text] [Related]
16. Immunolocalization of cannabinoid receptor type 1 and CB2 cannabinoid receptors, and transient receptor potential vanilloid channels in pterygium.
Assimakopoulou M; Pagoulatos D; Nterma P; Pharmakakis N
Mol Med Rep; 2017 Oct; 16(4):5285-5293. PubMed ID: 28849159
[TBL] [Abstract][Full Text] [Related]
17. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM; Duncan M; Di Marzo V; Pertwee RG
Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
[TBL] [Abstract][Full Text] [Related]
18. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
